Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 252 for “"Docetaxel"”.
-
Docetaxel Pharmacogenetics and its Influence on the Pharmacokinetics/Pharmacodynamics of Docetaxel in Asian Nasopharyngeal Cancer Patients
… the genetic basis of inherited differences in docetaxel pharmacokinetics and pharmacodynamic in local Chinese nasopharyngeal cancer patients (N = 50). The following genes involved in the biochemical pathways of docetaxel were studied: regulatory nuclear receptors (PXR, CAR, RXRa, HNF4a), drug …
-
A multi-compartment pharmacokinetic model of docetaxel
Docetaxel is a clinically active chemotherapeutic agent commonly used in the treatment of solid tumors. It is administered within a micelle encapsulation, polysorbate 80, via intravenous infusion. Docetaxel is known to have a high degree of interpatient variability in its pharmacokinetic behaviour. …
-
Docetaxel uptake and modulation of P-gpmediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines
Treatment with the taxanes, docetaxel and paclitaxel, can result in the emergence of multi-drug resistance (MDR) mediated by P-gp (MDR-1, ABCB1), which is an effective cellular efflux pump for both agents. This thesis was undertaken to examine the contribution of drug transport mechanisms to …
-
Residual breast cancer metabolic phenotype after docetaxel treatment
… of residual breast cancer which survived docetaxel treatment, \(in\) \(vitro\) and \(in\) \(vivo\), quantifying polar metabolite levels and conducting pathway tracing and metabolic flux analysis using stable isotope (\(^{13}\)C) labelled tracers. \(In\) \(vitro\) residual cells presented a …
-
Characterisation of Docetaxel-Resistance in Castrate Resistant Prostate Cancer
… (CRPC) being the lethal stage of the disease. Docetaxel-based chemotherapy is the standard-of-care for CRPC patients. Inevitably, those patients who respond, develop resistance to chemotherapy. Limited success of clinical trials emanating from conventional candidate-based approaches highlights …
-
Ενδονουκλεάσες – απόπτωση και συγκριτική μελέτη της αντοχής του μη - μικροκυτταρικού καρκίνου του πνεύμονα σε δύο σχήματα χημειοθεραπείας με Docetaxel / Cisplatin vs Docetaxel / Gemcitabine
… first-line chemotherapy combinations with docetaxel-gemcitabine or docetaxel-cisplatin at the «Sotiria» Hospital of Chest Diseases of Athens. The study has been approved by the institutional ethics committee and all patients gave their informed consent for the use of the tissue material for …
-
Bladder tissue distribution of paclitaxel and docetaxel from polymeric nanoparticles
Taxane based drugs are commonly used second-line adjuvant therapies for the treatment of superficial bladder cancer. However, the effectiveness of these drugs following intravesical instillation is limited, because of a short drug residence time and poor drug penetration into the bladder wall. The …
-
Verläufe ambulanter Docetaxel-Firstline-Chemotherapien bei Patienten mit kastrationsresistentem Prostatakarzinom
Einleitung: Docetaxel ist ein etabliertes Chemotherapeutikum beim kastrationsresistenten Prostatakazinom (CRPCa), da es zu einer Verlängerung des Gesamtüberlebens führt (Tannock IF et al. 2004, Petrylak DP et al. 2004). In der klinischen Praxis liegen jedoch differente Bedingungen im Vergleich zu …
-
Biodistribuição de samário -153- EDTMP em ratos TRATADOS com docetaxel
… fosfonato (EDTMP-153Sm). O docetaxel, um taxano com ação sobre tumores avançados de mama e próstata, tem-se apresentado como uma nova opção de tratamento quimioterápico. Muitos pacientes fazem uso simultâneo de EDTMP-153Sm e docetaxel. Este estudo procurou avaliar a …
-
Targeted chemotherapy: Trastuzumab tailored Docetaxel loaded PLGA nanoaparticles for HER2 positive breast cancer
… rationale of using trastuzumab (TmAb) tailored docetaxel (Doc) loaded poly-D, L-lactide-co-glycolide (PLGA) nanoparticles (NPs) to target the human epidermal receptor-2 (HER2) receptors of breast cancer cells. Utilizing emulsification solvent evaporation technique, pre-activated drug loaded NPs …
-
Modulation of nanoparticle uptake, intracellular distribution, and retention with docetaxel to enhance radiotherapy
… tumor. We chose gold nanoparticles (GNPs) and docetaxel (DTX) as our choice of two radiosensitizing agents. They have a different mechanism of action which could lead to synergistic effect. Our first goal was to assess the variation in GNP uptake, distribution, and retention in the presence of …
-
Optimization of Survivin Dimerization Inhibitors for the Treatment of Docetaxel-Resistant Prostate Cancer
… common cause of cancer-related mortality in men. Docetaxel is the first cytotoxic agent to show modest improvements in overall survival rate in patients with metastatic prostate cancer. Unfortunately, over half of these patients do not respond to treatment and ultimately all develop resistance. …
-
Potential use of Aneustat for improvement of docetaxel-based therapy of advanced prostate cancer
… prostate cancer (mPCa) is currently incurable. Docetaxel-based chemotherapy, used as first-line treatment for advanced PCa, is marginally effective. As PCa is a heterogeneous disease, use of therapeutics targeting multiple pathways may improve its treatment outcome. Aneustat is first-of-a-class …
-
Docetaxel Nanostructured lipid carrier with enhanced blood brain barrier permeability for targeted glioblastoma therapy
… agents to pass the blood-brain barrier (BBB). Docetaxel a hydrophobic anticancer drug used alone and in combination with other drugs to treat tumours is a P-glycoprotein substrate and suffers from the drawback of non-specific cytotoxicity and limited accumulation in the brain. To address these …
-
Wirksamkeit und Toxizität von Docetaxel in der Therapie von Malignomen des Kopf-Hals-Bereichs
… Untersuchung der Effektivität und Toxizität von Docetaxel im Rahmen einer Kombinationschemotherapie mit Cisplatin und 5-Fluorouracil in unterschiedlichen Therapieansätzen bei Patienten mit einem diagnostizierten Plattenepithelkarzinom im Kopf-Hals- Bereich an der Charité Universitätsmedizin. …
-
RNA HELICASE, DP103 AS A PREDICTIVE BIOMARKER FOR DOCETAXEL RESPONSE IN ERa-POSITIVE BREAST CANCER
… IN A RETROSPECTIVE PHASE II STUDY INVOLVING DOCETAXEL BASED NEOADJUVANT THERAPY, CLINICAL RESPONDERS WERE CHARACTERIZED BY A PROGRESSIVE DECREASE IN DP103 EXPRESSION. THIS DECREASE IN DP103 EXPRESSION WAS ONLY OBSERVED IN RESPONDERS WITH ERA-POSITIVE STATUS AND NOT ERA-NEGATIVE STATUS. …
-
Development of a nanoparticulate formulation of docetaxel for the treatment of non-muscle-invasive bladder cancer
… nanoparticulate carriers of docetaxel (DTX) offered an improved and effective formulation of the drug for intravesical delivery in mice. The present work describes the effect of concentration and exposure times of three HPG-C₈/₁₀-MePEG-NH₂’s with increasing degrees of …
-
Contribuição da expressão de c-kit na aquisição de quimiorresistência ao docetaxel no câncer de próstata
… dessa neoplasia ao agente quimioterápico Docetaxel. Métodos: estudo experimental, utilizando células PC3, derivadas de metástases de câncer de próstata humano andrógeno-independente e C42b derivadas de metástases ósseas de câncer de próstata de coluna lombar de ratos atímicos . Ambas …
-
Evaluation of the combination treatment docetaxel and JQ1 in 2D and 3D preclinical models of prostate cancer
… than JQ1 alone. This study shows that JQ1 and docetaxel might serve as an effective combination therapy for patients with mPCa. We assessed the combination therapy in 2D and 3D preclinical models, and we also evaluated the susceptibility of 2D-cultured LNCaP cells and 3D-cultured LNCaP …
Page 1 of 13